We are live on ! Find out more
APGE icon

Apogee Therapeutics

168 hedge funds and large institutions have $2.3B invested in Apogee Therapeutics in 2025 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 50 increasing their positions, 59 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

57% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 21

50% more call options, than puts

Call options by funds: $14.3M | Put options by funds: $9.54M

7% more funds holding

Funds holding: 157168 (+11)

5.09% more ownership

Funds ownership: 128.52%133.61% (+5.1%)

0% more funds holding in top 10

Funds holding in top 10: 44 (0)

12% less capital invested

Capital invested by funds: $2.62B → $2.3B (-$320M)

15% less repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 59

Holders
168
Holders Change
+11
Holders Change %
+7.01%
% of All Funds
2.25%
Holding in Top 10
4
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
33
Increased
50
Reduced
59
Closed
21
Calls
$14.3M
Puts
$9.54M
Net Calls
+$4.8M
Net Calls Change
+$6.41M
Name Holding Trade Value Shares
Change
Change in
Stake
VA
1
VR Adviser
New York
$317M
Fidelity Investments
2
Fidelity Investments
Massachusetts
$280M -$223K -5,756 -0.1%
Wellington Management Group
3
Wellington Management Group
Massachusetts
$205M +$37.4M +968,391 +21%
BlackRock
4
BlackRock
New York
$109M -$5.19M -134,129 -4%
RI
5
RTW Investments
New York
$101M
DCM
6
Driehaus Capital Management
Illinois
$87.4M -$10.3M -265,747 -10%
Vanguard Group
7
Vanguard Group
Pennsylvania
$77.8M -$580K -14,991 -0.7%
FFM
8
Fairmount Funds Management
Pennsylvania
$76.5M
Janus Henderson Group
9
Janus Henderson Group
United Kingdom
$71.3M +$25.5M +658,733 +58%
Mercer Global Advisors
10
Mercer Global Advisors
Colorado
$61.3M +$35.6M +920,079 +128%
RCM
11
RA Capital Management
Massachusetts
$58.6M
B
12
Braidwell
Connecticut
$57.5M
State Street
13
State Street
Massachusetts
$49.1M -$5.93M -153,364 -10%
AllianceBernstein
14
AllianceBernstein
Tennessee
$47.9M -$2.87M -74,235 -5%
AAA
15
Affinity Asset Advisors
New York
$43M +$8.49M +219,471 +24%
PA
16
Perceptive Advisors
New York
$41.9M +$2.92M +75,535 +7%
WP
17
Woodline Partners
California
$39.6M +$1.76M +45,445 +4%
JP Morgan Chase
18
JP Morgan Chase
New York
$36M +$35.8M +925,376 +2,484%
PBA
19
Paradigm Biocapital Advisors
New York
$35.9M -$12.5M -322,059 -25%
Franklin Resources
20
Franklin Resources
California
$32.7M +$382K +9,888 +1%
Geode Capital Management
21
Geode Capital Management
Massachusetts
$31.2M +$757K +19,582 +2%
T. Rowe Price Associates
22
T. Rowe Price Associates
Maryland
$30.7M -$8.92M -230,745 -22%
Adage Capital Partners
23
Adage Capital Partners
Massachusetts
$27.2M +$18.8M +486,800 +203%
UBS Group
24
UBS Group
Switzerland
$26.2M +$6.21M +160,623 +30%
SL
25
Siren LLC
Connecticut
$22.2M -$5.89M -152,331 -20%

APGE Hedge Fund Activity: Q1 2025 in Review

168 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Apogee Therapeutics (APGE) for Q1 2025, worth a combined $2.3B — down 12% from $2.62B a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new APGE positions and 21 closed out — a net gain of 12 holders — while 50 added to existing stakes and 59 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $37.4M. The largest seller was Jefferies Financial Group, cutting an estimated $18M.

  • 168 institutional investors held Apogee Therapeutics (APGE) as of Q1 2025, up from 157 in Q4 2024.
  • Funds reported $2.3B of Apogee Therapeutics stock for Q1 2025, down 12% quarter-over-quarter.
  • 33 funds opened new Apogee Therapeutics positions in Q1 2025 and 21 closed out, a net change of +12 holders.
  • The largest Apogee Therapeutics buyer in Q1 2025 was Wellington Management Group, an estimated $37.4M added.
  • The largest Apogee Therapeutics seller in Q1 2025 was Jefferies Financial Group, an estimated $18M sold.

Based on aggregated 13F filings for Q1 2025.